Stability study of umbilical cord mesenchymal stem cells formulation in large-scale production
10.16438/j.0513-4870.2023-1063
- VernacularTitle:人脐带间充质干细胞制剂大规模生产中稳定性研究
- Author:
Wang-long CHU
1
;
Tong-jing LI
1
;
Yan SHANGGUAN
1
;
Fang-tao HE
1
;
Jian-fu WU
1
;
Xiu-ping ZENG
1
;
Tao GUO
1
;
Qing-fang WANG
1
;
Fen ZHANG
1
;
Zhen-zhong ZHONG
1
,
2
;
Xiao LIANG
1
,
2
;
Jun-yuan HU
1
,
2
;
Mu-yun LIU
3
,
4
Author Information
1. Shenzhen Beike Biotechnology Co., Ltd., Shenzhen 518057, China
2. Harbin Beike Health Technology Co., Ltd., Harbin 150000, China
3. Shenzhen Kenuo Medical Laboratory, Shenzhen 518000, China
4. National Engineering Research Center of Foundational Technologies for CGT Industry, Shenzhen 518000, China
- Publication Type:Research Article
- Keywords:
umbilical cord mesenchymal stem cell;
production;
cell stock solution;
cell intermediate product;
cell product;
stability
- From:
Acta Pharmaceutica Sinica
2024;58(3):743-750
- CountryChina
- Language:Chinese
-
Abstract:
Umbilical cord mesenchymal stem cells (UC-MSCs) have been widely used in regenerative medicine, but there is limited research on the stability of UC-MSCs formulation during production. This study aims to assess the stability of the cell stock solution and intermediate product throughout the production process, as well as the final product following reconstitution, in order to offer guidance for the manufacturing process and serve as a reference for formulation reconstitution methods. Three batches of cell formulation were produced and stored under low temperature (2-8 ℃) and room temperature (20-26 ℃) during cell stock solution and intermediate product stages. The storage time intervals for cell stock solution were 0, 2, 4, and 6 h, while for intermediate products, the intervals were 0, 1, 2, and 3 h. The evaluation items included visual inspection, viable cell concentration, cell viability, cell surface markers, lymphocyte proliferation inhibition rate, and sterility. Additionally, dilution and culture stability studies were performed after reconstitution of the cell product. The reconstitution diluents included 0.9% sodium chloride injection, 0.9% sodium chloride injection + 1% human serum albumin, and 0.9% sodium chloride injection + 2% human serum albumin, with dilution ratios of 10-fold and 40-fold. The storage time intervals after dilution were 0, 1, 2, 3, and 4 h. The reconstitution culture media included DMEM medium, DMEM + 2% platelet lysate, 0.9% sodium chloride injection, and 0.9% sodium chloride injection + 1% human serum albumin, and the culture duration was 24 h. The evaluation items were viable cell concentration and cell viability. The results showed that the cell stock solution remained stable for up to 6 h under both low temperature (2-8 ℃) and room temperature (20-26 ℃) conditions, while the intermediate product remained stable for up to 3 h under the same conditions. After formulation reconstitution, using sodium chloride injection diluted with 1% or 2% human serum albumin maintained a viability of over 80% within 4 h. It was observed that different dilution factors had an impact on cell viability. After formulation reconstitution, cultivation in medium with 2% platelet lysate resulted in a cell viability of over 80% after 24 h. In conclusion, the stability of cell stock solution within 6 h and intermediate product within 3 h meets the requirements. The addition of 1% or 2% human serum albumin in the reconstitution diluent can better protect the post-reconstitution cell viability.
